Business
Medincell Reports FY 2025-26 Annual Results
MONTPELLIER, France, June 16, 2026--Medincell (Paris:MEDCL): Key Financial Highlights
About this update from Medincell Sa
A year marked by solid execution, with MONTPELLIER, France, June 16, 2026 --( BUSINESS WIRE )--Medincell (Paris:MEDCL): Medincell continues to transition towards multiple commercialized innovative products based on its technology, increasingly supporting milestone and recurring royalty revenues. FY 2025–26 reflects this trend, with strong growth in UZEDY ® royalties and a disciplined increase in investments to support future growth. As anticipated, year-over-year comparisons are impacted by the absence of non-recurring milestone revenues recorded in the prior year, which affects the comparability of total revenues. Christophe Douat, CEO of Medincell, said: "FY 2025–26 reflects an important transition phase for Medincell. Building on UZEDY’s strong performance and the expected commercial launch of Olanzapine LAI by our partner Teva later this year, we are advancing the next phase of our ‘Shift to Growth’ strategy. We are building a pipeline of highly differentiated, innovation-driven products designed to deliver sustainable value for patients, partners and shareholders, while generating milestones and recurring high-margin revenues over time." For the full press release, please click on the following link: https://www.medincell.com/news/ About Medincell Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact. medincell.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260616763165/en/ Contacts David Heuzé Head of Corporate and Financial Communications, and ESG [email protected] / +33 (0)6 83 25 21 86 Grace Kim Chief Strategy Officer, U.S. Finance [email protected] / +1 (646) 991-4023